tazemetostat + daratumumab + pomalidomide + dexamethasone

This is a combination therapy regimen consisting of **tazemetostat**, **daratumumab**, **pomalidomide**, and **dexamethasone**. - **Tazemetostat** is a small molecule inhibitor of EZH2, an epigenetic regulator, used in the treatment of certain cancers. - **Daratumumab** is a monoclonal antibody targeting CD38, approved for use in multiple myeloma, and acts through direct tumor cell lysis and immunomodulatory effects. - **Pomalidomide** is an immunomodulatory drug (IMiD), structurally related to thalidomide and lenalidomide, with anti-neoplastic and immune-enhancing mechanisms, currently used in relapsed/refractory multiple myeloma. - **Dexamethasone** is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, used broadly as a supportive agent in antineoplastic regimens. The combination is being evaluated primarily for use in patients with relapsed/refractory multiple myeloma, generally those who have seen disease progression after standard therapies. While the combination of daratumumab, pomalidomide, and dexamethasone is FDA-approved and widely studied, the addition of tazemetostat is currently investigational in this context[2].